1. Home
  2. TU vs MRNA Comparison

TU vs MRNA Comparison

Compare TU & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Telus Corporation

TU

Telus Corporation

HOLD

Current Price

$11.50

Market Cap

21.2B

ML Signal

HOLD

Logo Moderna Inc.

MRNA

Moderna Inc.

HOLD

Current Price

$61.21

Market Cap

21.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TU
MRNA
Founded
1993
2010
Country
Canada
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.2B
21.6B
IPO Year
2000
2018

Fundamental Metrics

Financial Performance
Metric
TU
MRNA
Price
$11.50
$61.21
Analyst Decision
Hold
Hold
Analyst Count
4
12
Target Price
$17.63
$34.27
AVG Volume (30 Days)
5.5M
6.8M
Earning Date
05-07-2026
05-01-2026
Dividend Yield
9.96%
N/A
EPS Growth
N/A
21.77
EPS
N/A
N/A
Revenue
N/A
$19,263,000,000.00
Revenue This Year
$4.94
$9.36
Revenue Next Year
$2.76
$15.43
P/E Ratio
$25.82
N/A
Revenue Growth
N/A
4.29
52 Week Low
$11.33
$22.28
52 Week High
$16.74
$67.74

Technical Indicators

Market Signals
Indicator
TU
MRNA
Relative Strength Index (RSI) 30.61 65.23
Support Level N/A $45.69
Resistance Level $12.64 N/A
Average True Range (ATR) 0.23 4.49
MACD -0.07 1.59
Stochastic Oscillator 15.35 70.88

Price Performance

Historical Comparison
TU
MRNA

About TU Telus Corporation

Telus is one of the Big Three wireless service providers in Canada, with over 10 million mobile phone subscribers nationwide constituting almost 30% of the total market. It is the incumbent local exchange carrier in the western Canadian provinces of British Columbia and Alberta, where it provides internet, television, and landline phone services. It also has a small wireline presence in eastern Quebec. Mostly because of recent acquisitions, more than 20% of Telus' sales now come from nontelecom businesses, most notably in the international business services, health, security, and agriculture industries. The firm has a 55% economic stake in Telus International.

About MRNA Moderna Inc.

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Share on Social Networks: